### 25695 Federal Register / Vol. 76, No. 87 / Thursday, May 5, 2011 / Notices

well as updates from approximately half of the NORA Sector Councils on their progress, priorities, and implementation plans to date, including the NORA Manufacturing, Public Safety, Services, and Wholesale and Retail Trade Sector Councils. Updates will also be given on the Mid-Decade Review of NORA, the NORA Symposium 2011, and at least one NIOSH Program that is working on several NORA priorities, e.g., the NIOSH Economics Program. After each update, there will be time to discuss partnership opportunities.

Status: The meeting is open to the public, limited only by the capacities of the conference call and conference room facilities. There is limited space available in the meeting room (capacity 34). Therefore, information to allow participation in the meeting through the Internet (to see the slides) and a teleconference call (capacity 50) will be provided to registered participants. Participants are encouraged to consider attending by this method. Each participant is requested to register for the free meeting by sending an e-mail to noracoordinator@cdc.gov containing the participant’s name, organization name, contact telephone number on the day of the meeting, and preference for participation by Web meeting (requirements include: Computer, Internet connection, and telephone, preferably with ‘mute’ capability) or in person. An e-mail confirming registration will include the details needed to participate in the Web meeting. Non-U.S. citizens are encouraged to participate in the Web meeting. Non-U.S. citizens who do not register to attend in person on or before June 6, 2011, will not be granted access to the meeting site and will not be able to attend the meeting in-person due to mandatory security clearance procedures at the Patriots Plaza facility.

Background: NORA is a partnership program to stimulate innovative research in occupational safety and health leading to improved workplace practices. Unveiled in 1996, NORA has become a research framework for the nation. Diverse parties collaborate to identify the most critical issues in workplace safety and health. Partners then work together to develop goals and objectives for addressing those needs and to move the research results into practice. The NIOSH role is facilitator of the process. For more information about NORA, see http://www.cdc.gov/niosh/ nora/about.html

.

Since 2006, NORA has been structured according to industrial sectors. Ten major sector groups have been defined using the North American Industrial Classification System (NAICS). After receiving public input through the Web and town hall meetings, ten NORA Sector Councilshave been working to define sectorspecific strategic plans for conducting research and moving the results into widespread practice. During 2008–10, most of these Councils posted draft strategic plans for public comment and eight have posted finalized National Sector Agendas after considering comments on the drafts. For the National Sector Agendas, see http:// www.cdc.gov/niosh/nora/.

**FOR FURTHER INFORMATION CONTACT :**  Sidney C. Soderholm, PhD, NORA Coordinator, e-mail noracoordinator@cdc.gov, telephone (202) 245–0665.

Dated: April 27, 2011. Tanja Popovic, Deputy Associate Director for Science, Centers for Disease Control and Prevention.
[FR Doc. 2011–10950 Filed 5–4–11; 8:45 am]

**BILLING CODE 4163–19–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES** 

**Centers for Disease Control and Prevention** 

**[Docket No. CDC–2011–0004]**

**Public Health Information Network (PHIN) Messaging Guide for Syndromic**  **Surveillance**

**AGENCY :**  Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION :**  Notice with comment period.

**SUMMARY :**  The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS) is requesting public comment on the draft PHIN Messaging Guide for Syndromic Surveillance. The document translates the business requirement recommendations from the International Society for Disease Surveillance to technical specifications to support meaningful use of electronic health records for syndromic surveillance. Comments will be used to inform and finalize the Messaging Guide.

**DATES :**  Written comments must be received on or before June 20, 2011. See Addresses for instructions to submit
comment.

**ADDRESSES :**  You may submit written comments to the following address: Public Health Informatics and Technology Program Office, Centers for Disease Control and Prevention, 1600 Clifton Road, NE., Mailstop E–76, Atlanta, Georgia 30329. Attn: PHIN Syndromic Surveillance Messaging Guide Comments (Docket No. CDC– 2011–0004),

You may also submit written comments electronically to http:// www.regulations.gov. Comments must be identified by Docket No. CDC–2011– 0004. Please follow directions at http:// wwww.regulations.gov to submit
comments.

All relevant comments received will be posted publicly without change, including any personal or proprietary information provided. An electronic version of the draft is available to download at http://www.regulations.gov and http://www.cdc.gov/phin/library/ 2011/guides/Syndromic

_ Surveillance

_ Implementation

_ Guide

_ Release

_ 1

_ 4.pdf.

Written comments, identified by Docket No. CDC–2011–0004, will be available for public inspection Monday through Friday, except for legal holidays, from 9 a.m. until 5 p.m., Eastern Daylight Time, at 1600 Clifton Road, NE., Atlanta, Georgia 30333. Please call ahead to (404) 639–6100 and ask for a representative from the Public Health Informatics and Technology Program Office to schedule your visit. Comments may also be viewed at http:// www.regulations.gov.

**FOR FURTHER INFORMATION CONTACT :**  Nikolay Lipskiy, Centers for Disease Control and Prevention, Public Health Informatics and Technology Program Office; l600 Clifton Road, NE., Mailstop E–76, Atlanta, Georgia 30329, phone
404–498–6100.

**SUPPLEMENTARY INFORMATION :**  The International Society for Disease Surveillance (ISDS), with the support of CDC, convened a Meaningful Use Workgroup to define current syndromic surveillance business standards and data requirements. The goal of the ISDS workgroup is to ensure that public health authorities, health care professionals, Electronic Health Record (EHR) technology developers, and the HHS Office of the National Coordinator for Health Information Technology have business standards that will best support meaningful use of EHRs for syndromic surveillance. The Final Recommendation from ISDS (available
at http://www.syndromic.org/uploads/ files/ISDSRecommendation

_FINAL.pdf) was published in early January 2011. As the ISDS workgroup developed recommendations, the CDC Public Health Informatics and Technology Program Office, worked to translate the business requirement recommendations to technical specifications. This notice announces a draft PHIN Messaging


### 25696 Federal Register / Vol. 76, No. 87 / Thursday, May 5, 2011 / Notices

Guide for Syndromic Surveillance available for public comment at http:// www.regulations.gov and http:// www.cdc.gov/phin/library/2011/guides/ Syndromic

_ Surveillance

_ Implementation

_ Guide

_ Release

_ 1

_ 4.pdf

Dated: April 27, 2011. Tanja Popovic, Deputy Associate Director for Science, Centers for Disease Control and Prevention.
[FR Doc. 2011–10949 Filed 5–4–11; 8:45 am]

**BILLING CODE 4163–18–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES** 

**Food and Drug Administration**

**[Docket No. FDA–2009–D–0322]**

**Guidance for Industry on Dosage Delivery Devices for Orally Ingested**  **OTC Liquid Drug Products; Availability**

**AGENCY :**  Food and Drug Administration, HHS.

**ACTION :**  Notice.

**SUMMARY :**  The Food and Drug Administration (FDA) is announcing the availability of a guidance for industry entitled ‘‘ Dosage Delivery Devices for Orally Ingested OTC Liquid Drug Products. ’’ This document is intended to provide guidance to firms that are manufacturing, marketing, ordistributing orally ingested over-thecounter (OTC) liquid drug products packaged with dosage delivery devices (e.g., calibrated cups, droppers, syringes, or spoons). FDA is issuing this guidance because of ongoing concerns about potentially serious accidental drug overdoses that can result from the use of dosage delivery devices with markings that are inconsistent or incompatible with the labeled dosage directions for orally ingested OTC liquid drug products.

**DATES :**  Submit either electronic or written comments on Agency guidances at any time.

**ADDRESSES :**  Submit written requests for single copies of this guidance to the Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, rm. 2201, Silver Spring, MD 20993–0002. Send one self-addressed adhesive label to assist that office in processing your requests. See the **SUPPLEMENTARY**
**INFORMATION** section for electronic access to the guidance document.

Submit electronic comments on the guidance to http://www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA– 305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

**FOR FURTHER INFORMATION CONTACT :**  Spencer Salis, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Building 51, rm. 5216, Silver Spring, MD 20993–0002, 301–
796–3327.

**SUPPLEMENTARY INFORMATION :**  I. Background

FDA is announcing the availability of a guidance for industry entitled ‘‘ Dosage Delivery Devices for Orally Ingested OTC Liquid Drug Products. ’’ The Agency has determined that many orally ingested OTC liquid drug products in the marketplace are packaged with dosage delivery devices that bear markings that are inconsistent with the labeled dosage directions, contain superfluous markings, or are missing necessary markings. FDA is issuing this guidance because of ongoing concerns about potentially serious accidental drug overdoses that can result from the use of dosage delivery devices with markings that are inconsistent or incompatible with the labeled dosage directions for orally ingested OTC drug products. FDA recommends that dosage delivery devices be included for all orally ingested OTC drug products that are liquid formulations, that they should bear markings that are consistent with the labeled dosage directions, and that they should be labeled in a manner that attempts to ensure that they are used only with the products with which they are included.

In the Federal Register of November 5, 2009 (74 FR 57319), FDA announced the availability of a draft guidance for industry entitled ‘‘ Dosage Delivery Devices for Over-the-Counter Liquid Drug Products. ’’ The notice gave interested persons an opportunity to comment by February 2, 2010. We received a number of comments from individuals, firms, and consumer groups. We have carefully considered the comments and, where appropriate, have made corrections, added information, or clarified the information in the guidance in response to the comments or on our own initiative.

This guidance is being issued consistent with FDA’s good guidance practices regulation (21 CFR 10.115). The guidance represents the Agency’s current thinking on dosage delivery devices for orally ingested OTC liquid drug products. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations.

II. Comments

Interested persons may submit to the Division of Dockets Management (see

**ADDRESSES** ) either electronic or written comments regarding this document. It is only necessary to send one set of comments. It is no longer necessary to send two copies of mailed comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

III. Electronic Access

Persons with access to the Internet may obtain the document at either http://www.fda.gov/Drugs/Guidance ComplianceRegulatoryInformation/ Guidances/default.htm or http://www. regulations.gov.

Dated: April 28, 2011. Leslie Kux, Acting Assistant Commissioner for Policy.
[FR Doc. 2011–10965 Filed 5–4–11; 8:45 am]

**BILLING CODE 4160–01–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES** 

**Health Resources and Services Administration** 

**National Advisory Committee on Rural Health and Human Services; Notice of**  **Meeting**

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), notice is hereby given that the following committee will convene its sixty-seventh meeting.

Name: National Advisory Committee on Rural Health and Human Services.

Dates and Times: June 15, 2011, 9 a.m.– 4:45 p.m., June 16, 2011, 9 a.m.–4:45 p.m., June 17, 2011, 8:45 a.m.–10:30 a.m.

Place: Park Place Hotel, 300 East State Street, Traverse City, MI 49684. (231) 946–
5000.

Status: The meeting will be open to the public.

Purpose: The National Advisory Committee on Rural Health and Human Services provides advice and recommendations of health and human services in rural areas.

Agenda: Wednesday morning, at 9 a.m., the meeting will be called to order by the Chairperson of the Committee, the Honorable Ronnie Musgrove. The first three presentations will be overviews of rural Michigan and the relevant health indicators. The remainder of the day the Committee will hear presentations on two of the chosen